Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cantabio Pharmaceuticals Inc. (OTC: CTBO).

Full DD Report for CTBO

You must become a subscriber to view this report.


Recent News from (OTC: CTBO)

Cantabio Pharmaceuticals to Present Positive in vivo Efficacy Data in a Mice Model of Parkinson's disease from Its DJ-1 Protein Targeting Therapeutic Program at the Neuro4D Conference in Mainz, Germany
SAN FRANCISCO, May 09, 2018 (GLOBE NEWSWIRE) -- Cantabio Pharmaceuticals Inc. (OTCQB:CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's (AD), Parkinson's (PD) and other related neurodegenerative diseases, today announced that Dr. Gergely Tot...
Source: GlobeNewswire
Date: May, 09 2018 08:17
Key events next week - healthcare (continued #6)
Wednesday  (3/14): Nary an event. More news on: BioTime, Inc, Cantabio Pharmaceuticals Inc., Valeritas Holdings, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: March, 09 2018 10:03
Cantabio Pharmaceuticals to Present Results from its Tau Protein Targeting Therapeutic Program for the treatment of Alzheimer's Disease at the Advances in Alzheimer's and Parkinson's Therapies, An AAT-AD/PD Focus Meeting in Torino, Italy
SAN FRANCISCO, CA --(Marketwired - February 26, 2018) - Cantabio Pharmaceuticals, Inc. (OTCQB: CTBO) , a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's, Parkinson's and other related neurodegenerative diseases, today announced that Dr. Gergely T&#x...
Source: Marketwired
Date: February, 26 2018 08:30
Cantabio Pharmaceuticals to Present Update from Its DJ-1 Protein Targeting Therapeutic Program for the Treatment of Parkinson's Disease at Advances in Alzheimer's and Parkinson's Therapies, An AAT-AD/PD Focus Meeting in Torino, Italy
SAN FRANCISCO, CA --(Marketwired - January 22, 2018) - Cantabio Pharmaceuticals Inc. (OTCQB: CTBO) , a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's, Parkinson's and other related neurodegenerative diseases, today announced that Dr. Gergely Toth, ...
Source: Marketwired
Date: January, 22 2018 08:30
Cantabio Pharmaceuticals to Present at 2017 Silicon Valley Bank Healthcare Capital and Connections Summit in Shanghai
SAN FRANCISCO, CA --(Marketwired - September 13, 2017) - Cantabio Pharmaceuticals, Inc. (OTCQB: CTBO) , a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's, Parkinson's and other related neurodegenerative diseases, today announced that its CEO, Dr Ger...
Source: Marketwired
Date: September, 13 2017 08:24
Cantabio announces publication of study on a mechanism by which the DJ-1 protein loses its defensive function in neurodegenerative disease conditions
SUNNYVALE, CA --(Marketwired - September 11, 2017) - Cantabio Pharmaceuticals, Inc. (OTCQB: CTBO) ("Cantabio" or the "Company"), a preclinical stage pharmaceutical company developing disease modifying therapeutics for Alzheimer's Disease (AD), Parkinson's Disease (PD) and related neurod...
Source: Marketwired
Date: September, 11 2017 08:30
Cantabio Announces Publication of Study Results by University of Cambridge researchers in ACS Chemical Neuroscience
SUNNYVALE, CA --(Marketwired - July 06, 2017) - Cantabio Pharmaceuticals, Inc. (OTCQB: CTBO) ("Cantabio" or the "Company"), a preclinical stage pharmaceutical company developing disease modifying therapeutics for Alzheimer's, Parkinson's and related neurological disorders, today announc...
Source: Marketwired
Date: July, 06 2017 08:00
Cantabio Pharmaceuticals to Present Update from Its DJ-1 Protein Targeting Therapeutic Program for the Treatment of Parkinson's Disease at the 13th International Conference on Alzheimer's and Parkinson's Disease
SAN FRANCISCO, CA --(Marketwired - March 28, 2017) - Cantabio Pharmaceuticals Inc. (OTCQB: CTBO) , a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's, Parkinson's and other related neurodegenerative diseases, today announced that Dr. Gergely Toth, Ca...
Source: Marketwired
Date: March, 28 2017 08:30
Cantabio Pharmaceuticals to Present at the 2nd Annual Neuroscience BioPartnering and Investment Forum at the New York Academy of Sciences in New York
SAN FRANCISCO, CA --(Marketwired - March 14, 2017) - Cantabio Pharmaceuticals, Inc. (OTCQB: CTBO) , a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's, Parkinson's and other related neurodegenerative diseases, today announced that the company has bee...
Source: Marketwired
Date: March, 14 2017 08:30
Cantabio Pharmaceuticals to Present Results from Its Tau Protein Targeting Therapeutic Program for the Treatment of Alzheimer's Disease at the 13th International Conference on Alzheimer's and Parkinson's Disease
SAN FRANCISCO, CA --(Marketwired - February 14, 2017) - Cantabio Pharmaceuticals Inc. (OTCQB: CTBO) , a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's, Parkinson's and other related neurodegenerative diseases, today announced that Dr. Gergely Toth,...
Source: Marketwired
Date: February, 14 2017 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-07-200.0250.0230.0250.02187,614
2018-07-190.0270.0220.0270.022144,600
2018-07-180.02240.02990.02990.022413,200
2018-07-170.0350.0260.0350.02651,740
2018-07-16N/A0.037N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-07-20160,500187,61485.5480Short
2018-07-19121,000144,60083.6791Short
2018-07-185,30013,20040.1515Short
2018-07-1732,44051,74062.6981Short
2018-07-1320,00030,20066.2252Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CTBO.


About Cantabio Pharmaceuticals Inc. (OTC: CTBO)

Logo for Cantabio Pharmaceuticals Inc. (OTC: CTBO)

Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company focussing on commercializing novel therapies and the intellectual property generated from our research and development activities for Parkinson s disease PD , Alzheimer s disease AD and other related neurodegenerative diseases. Our strategy integrates therapeutic focus, target family biophysics, drug discovery technology and expertise into an innovative drug discovery approach, which is currently identifying and developing small molecule pharmacological chaperones for clinical trials. In addition, the company is developing therapeutic proteins that can pass through the blood brain barrier to supplement existing levels of proteins which display loss of function during disease conditions.

 

Contact Information

 

 

Current Management

  • Gergely Toth / CEO
    • Dr. Toth received his MSc in Chemistry at the University of Szeged and later his PhD from the Department of Biomedical Sciences at Creighton University in . He was a postdoctoral fellow at the Department of Molecular Biology at the University of California at Berkeley between and . Dr. Toth is a graduate of the Global BioExecutive program of the BioExecutive Institute University of California, Berkeley, Haas School of Business . Dr. Toth also received an Executive MBA from the University of Cambridge UK in . Dr. Toth is the founder and CEO of Gardedam Therapeutics California, USA, , an early state biopharmaceutical company focusing on novel drug discovery research for Parkinson s and Alzheimer s disease. Dr. Toth is also affiliated with the University of Cambridge in the UK, Department of Clinical Neurosciences, Wolfson Brain Imaging Centre since , where he has been an Investigator in the NIHR Biomedical Research Unit on Dementia and of the Neurodegenerative Disease Initiative on AD funded by the Wellcome Trust and Medical Research Council. In addition, Dr. Toth heads the Neurodegenerative Disease Drug Discovery research group since at the Academy of Sciences of Hungary in Budapest. Dr. Toth is also a visiting lecturer in the Business of Biotechnology at the School of Pharmacy at the University College London.
  • Thomas Roger Sawyer / COO
    • Dr. Thomas Sawyer is the Chief Operations Officer of Cantabio Pharmaceuticals, combining a background in academic research with years of experience in entrepreneurship, consulting and private equity investment in sectors including biotechnology, IT, logistics and natural resources across the globe. He has worked on M amp A activities for private and public companies in the U.S., Europe and Africa and has experience in raising capital, IPOs, mergers and in CEO/CTO roles for startup and private equity backed ventures. Dr. Sawyer holds a Ph.D. in Life Sciences from the University of Glasgow, an Executive M.B.A. from the University of Cambridge and is a visiting lecturer on Corporate Finance at the University of Exeter. Dr. Sawyer combines a strong technical background with business development, corporate finance and operations, and is an active mentor on the Accelerate Cambridge business accelerator program at the University of Cambridge.
  • Simon Peace / CFO
    • Simon Peace is the Chief Financial Officer of Cantabio Pharmaceuticals. Mr. Peace is a qualified accountant with extensive experience in medical technology and life sciences. In addition to holding CFO appointments in various small companies, he has accumulated extensive global business experience at SmithKline Beecham, Cable amp Wireless, GE Capital and GE Healthcare. Most recently, Mr. Peace spent seven years practicing M amp A in medtech and life sciences at GE Healthcare, which saw him buying and selling businesses and setting up joint ventures across Europe, U.S., Russia and the Middle East. Mr. Peace is qualified to the Chartered Institute of Management Accountants and holds a B.Sc. in Natural Sciences from the University of Durham, an M.Sc. in Manufacturing Management from the University of Bradford and an Executive M.B.A. from the University of Cambridge Judge Business School. He is also a member of the Finance and Tax Advisory Committee of the BioIndustry Association.
  • Simon Peace / Audit Committee Member, Compensation Committee Member, Nominating Committee Member
    • Simon Peace is the Chief Financial Officer of Cantabio Pharmaceuticals. Mr. Peace is a qualified accountant with extensive experience in medical technology and life sciences. In addition to holding CFO appointments in various small companies, he has accumulated extensive global business experience at SmithKline Beecham, Cable amp Wireless, GE Capital and GE Healthcare. Most recently, Mr. Peace spent seven years practicing M amp A in medtech and life sciences at GE Healthcare, which saw him buying and selling businesses and setting up joint ventures across Europe, U.S., Russia and the Middle East. Mr. Peace is qualified to the Chartered Institute of Management Accountants and holds a B.Sc. in Natural Sciences from the University of Durham, an M.Sc. in Manufacturing Management from the University of Bradford and an Executive M.B.A. from the University of Cambridge Judge Business School. He is also a member of the Finance and Tax Advisory Committee of the BioIndustry Association.
  • Thomas Roger Sawyer /
    • Dr. Thomas Sawyer is the Chief Operations Officer of Cantabio Pharmaceuticals, combining a background in academic research with years of experience in entrepreneurship, consulting and private equity investment in sectors including biotechnology, IT, logistics and natural resources across the globe. He has worked on M amp A activities for private and public companies in the U.S., Europe and Africa and has experience in raising capital, IPOs, mergers and in CEO/CTO roles for startup and private equity backed ventures. Dr. Sawyer holds a Ph.D. in Life Sciences from the University of Glasgow, an Executive M.B.A. from the University of Cambridge and is a visiting lecturer on Corporate Finance at the University of Exeter. Dr. Sawyer combines a strong technical background with business development, corporate finance and operations, and is an active mentor on the Accelerate Cambridge business accelerator program at the University of Cambridge.
  • Gergely Toth / Nominating Committee Member
    • Dr. Toth received his MSc in Chemistry at the University of Szeged and later his PhD from the Department of Biomedical Sciences at Creighton University in . He was a postdoctoral fellow at the Department of Molecular Biology at the University of California at Berkeley between and . Dr. Toth is a graduate of the Global BioExecutive program of the BioExecutive Institute University of California, Berkeley, Haas School of Business . Dr. Toth also received an Executive MBA from the University of Cambridge UK in . Dr. Toth is the founder and CEO of Gardedam Therapeutics California, USA, , an early state biopharmaceutical company focusing on novel drug discovery research for Parkinson s and Alzheimer s disease. Dr. Toth is also affiliated with the University of Cambridge in the UK, Department of Clinical Neurosciences, Wolfson Brain Imaging Centre since , where he has been an Investigator in the NIHR Biomedical Research Unit on Dementia and of the Neurodegenerative Disease Initiative on AD funded by the Wellcome Trust and Medical Research Council. In addition, Dr. Toth heads the Neurodegenerative Disease Drug Discovery research group since at the Academy of Sciences of Hungary in Budapest. Dr. Toth is also a visiting lecturer in the Business of Biotechnology at the School of Pharmacy at the University College London.

Current Share Structure

  • Market Cap: $1,854,129 - 03/09/2018
  • Authorized: 250,000,000 - 02/08/2018
  • Issue and Outstanding: 36,355,468 - 02/08/2018
  • Float: 11,750,000 - 07/18/2016

 


Recent Filings from (OTC: CTBO)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 11 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 20 2018
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: February, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 27 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 14 2017
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: August, 18 2017
Correspondence from the SEC to the Filer
Filing Type: UPLOADFiling Source: edgar
Filing Date: August, 15 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 14 2017
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: August, 11 2017
Correspondence from the Filer to the SEC
Filing Type: CORRESPFiling Source: edgar
Filing Date: August, 10 2017

 

 


Daily Technical Chart for (OTC: CTBO)

Daily Technical Chart for (OTC: CTBO)


Stay tuned for daily updates and more on (OTC: CTBO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CTBO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CTBO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of CTBO and does not buy, sell, or trade any shares of CTBO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/